ALBERTA
FIRAZYR is covered by Alberta Health (Special Authorization)
Eligibility
For FIRAZYR to be eligible for coverage by Alberta Health, prescribers must submit a request for Special Authorization and approval must be granted before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.
Reimbursement Criteria
We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Alberta for your hereditary angioedema (HAE) patients who meet the following criteria:
For the treatment of acute attacks of confirmed type I or type II HAE in patients with C1-esterase inhibitor deficiency. Icatibant is to be used for:
- Acute non-laryngeal attack(s) of at least moderate severity, OR
- Acute laryngeal attack(s) of any severity
This medication must be prescribed by, or in consultation with, a physician experienced in the treatment of HAE.
Special Authorization may be granted for 12 months.
Patients will be limited to a maximum of two doses of icatibant per prescription at their pharmacy.
This product is eligible for auto-renewal.
OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.
Source: Alberta Health Drug Benefit List. April 2021.
https://www.ab.bluecross.ca/dbl/pdfs/dbl_full_list.pdf